EFIGALO

This brand name is authorized in Croatia, Estonia, Lithuania, Poland.

Active ingredients

The drug EFIGALO contains one active pharmaceutical ingredient (API):

1	Fingolimod UNII G926EC510T - FINGOLIMOD HYDROCHLORIDE
	Fingolimod is a sphingosine 1-phosphate receptor modulator. Fingolimod is metabolised by sphingosine kinase to the active metabolite fingolimod phosphate. By acting as a functional antagonist of S1P receptors on lymphocytes, fingolimod phosphate blocks the capacity of lymphocytes to egress from lymph nodes, causing a redistribution, rather than depletion, of lymphocytes.
	Read more about Fingolimod

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
L04AE01	Fingolimod	L Antineoplastic and immunomodulating agents → L04 Immunosuppressants → L04A Immunosuppressants → L04AE Sphingosine-1-phosphate (S1P) receptor modulators
Discover more medicines within L04AE01

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
EE	Ravimiamet	1807039, 1807040, 1807051, 1807062, 1807073, 1807084, 1807095, 1807107, 1807118
HR	Agencija za lijekove i medicinske proizvode	HR-H-665003707
LT	Valstybinė vaistų kontrolės tarnyba	1092182, 1092183, 1092184, 1092185, 1092186, 1092187, 1092188, 1092189, 1092190, 1092191, 1092192, 1092193, 1092194, 1092195, 1092196, 1092197, 1092198, 1092199, 1092200
PL	Rejestru Produktów Leczniczych	100430163